Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

May 19th 2023

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Dr Das on the Use of Neoadjuvant and Adjuvant Chemoimmunotherapy Regimens in NSCLC

May 18th 2023

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

First-line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefit in PD-L1+ NSCLC

May 17th 2023

Eftilagimod alpha plus pembrolizumab provided an overall survival benefit over what has been reported with historical controls when given as first-line treatment in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of at least 1%.

Osimertinib Plus Chemotherapy Improves PFS in EGFR+ Advanced NSCLC

May 17th 2023

The combination of osimertinib and platinum-based chemotherapy led to a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib alone in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.

Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC

May 16th 2023

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC

May 16th 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.

Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

May 16th 2023

The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.

Docetaxel Plus Ramucirumab After Standard Frontline Treatment Elicits Responses in NSCLC

May 16th 2023

The use of docetaxel and ramucirumab yielded antitumor activity and showcased a manageable safety profile in patients with non–small cell lung cancer who progressed on platinum-based chemotherapy and immune checkpoint inhibitors, according to data from the phase 2 SCORPION study.

Dr Khalil on the Future Investigations of Immunotherapy in NSCLC

May 15th 2023

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

Dr Khalil on Benefits Derived From the POSEIDON Regimen in Metastatic NSCLC

May 12th 2023

Maya Khalil, MD, discusses the use of first-line durvalumab plus tremelimumab in patients with non–small cell lung cancer enrolled in the phase 3 POSEIDON trial, and sheds light on histologies and mutations that are associated with increased benefit with this regimen.

Factors in Selecting IO Therapy for Patients With Advanced NSCLC

May 12th 2023

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

Considerations for Incorporating Perioperative Treatment in Resectable NSCLC

May 12th 2023

Before closing out their review of resectable NSCLC treatment strategies, key opinion leaders consider nuances in utilizing perioperative therapy in the current paradigm.

Dr Das on the Limited Landscape of Second-line Treatment Options in ES-SCLC

May 11th 2023

Devika Das, MD, MSHQS, discusses the activity and tolerability of lurbinectedin and topotecan as second-line regimens in extensive-stage small cell lung cancer.

Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

May 9th 2023

Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.

Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

May 9th 2023

Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.

Sintilimab Plus Chemo With or Without IBI305 Provides PFS Benefit in EGFR TKI–Pretreated EGFR+ NSCLC

May 8th 2023

The combination of sintilimab and chemotherapy with or without the bevacizumab biosimilar IBI305 produced a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with EGFR-mutated, nonsquamous non–small cell lung cancer who progressed after treatment with an EGFR TKI.

Dr Das on Updated Data Supporting the Use of Chemoimmunotherapy Regimens in ES-SCLC

May 5th 2023

Devika Das, MD, MSHQS,discusses updated data on the use of immunotherapy and platinum-based chemotherapy regimens in extensive-stage small cell lung cancer.

Adjuvant Treatment Strategies in Resectable Non–Small Cell Lung Cancer

May 5th 2023

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

What is the Role of Molecular Testing in Resectable Non–Small Cell Lung Cancer?

May 5th 2023

Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.

Aumolertinib Plus SRT Elicits Responses in Intracranial Oligometastatic EGFR+ NSCLC

May 4th 2023

Administration of aumolertinib until intracranial oligoprogression, followed by salvage stereotactic radiation therapy, produced central nervous system responses with acceptable tolerability in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.